Pharmacological therapy of lupus nephritis

JAMA

Volumn 293, Issue 24, 2005, Pages 3053-3060

  Fine, Derek M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

ADULT; ANAMNESIS; ARTICLE; CANCER RISK; CASE REPORT; FEMALE; HUMAN; INFECTION; INFERTILITY; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PUERPERIUM; CHEMICALLY INDUCED DISORDER; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; PATHOLOGY; PREMATURE OVARIAN FAILURE;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; OVARIAN FAILURE, PREMATURE;

EID: 20644438251     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.293.24.3053     Document Type: Article

References (58)

1. Martin JN Jr, Blake PG, Perry KG Jr, McCaul JF, Hess LW, Martin RW. The natural history of HELLP syndrome: patterns of disease progression and regression. Am J Obstet Gynecol. 1991;164:1500-1509.
2. Borenstein DG, Fye WB, Arnett FC, Stevens MB. The myocarditis of systemic lupus erythematosus: association with myositis. Ann Intern Med. 1978;89:619-624.
3. Moder KG, Miller TD, Tazelaar HD. Cardiac involvement in systemic lupus erythematosus. Mayo Clin Proc. 1999;74:275-284.
4. Raskin RJ, Haddock JB, Lawless OJ. Systemic lupus erythematosus with myocarditis complicating pregnancy. South Med J. 1983;76:258-260.
5. Cameron JS. Lupus nephritis. J Am Soc Nephrol. 1999;10:413-424.
6. Weening JJ, D'Agati VD, Schwartz MM, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int. 2004;65:521-530.
7. Rose BD, Schur PH, Falk RJ, Appel GB. Treatment of lupus nephritis. UpToDate Web site. Available at: http://patients.uptodate.com/topic.asp?file= glomrdis /16594&title=Lupus+nephritis. Accessibility verified May 17, 2005.
8. Huong DL, Papo T, Beaufils H, et al. Renal involvement in systemic lupus erythematosus: a study of 180 patients from a single center. Medicine (Baltimore). 1999;78:148-166.
9. Nossent JC, Henzen-Logmans SC, Vroom TM, Huysen V, Berden JH, Swaak AJ. Relation between serological data at the time of biopsy and renal histology in lupus nephritis. Rheumatol Int. 1991;11:77-82.
10. Gladman DD, Urowitz MB, Cole E, Ritchie S, Chang CH, Churg J. Kidney biopsy in SLE, I: a clinicalmorphologic evaluation. Q J Med. 1989;73:1125-1133.
11. Kashgarian M. Lupus nephritis: lessons from the path lab. Kidney Int. 1994;45:928-938.
12. Grande JP, Balow JE. Renal biopsy in lupus nephritis. Lupus. 1998;7:611-617.
13. Moroni G, Pasquali S, Quaglini S, et al. Clinical and prognostic value of serial renal biopsies in lupus nephritis. Am J Kidney Dis. 1999;34:530-539.
14. Contreras G, Roth D, Pardo V, Striker LG, Schultz DR. Lupus nephritis: a clinical review for practicing nephrologists. Clin Nephrol. 2002;57:95-107.
15. Austin HA III, Muenz LR, Joyce KM, et al. Prognostic factors in lupus nephritis: contribution of renal histologic data. Am J Med. 1983;75:382-391.
16. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant. 1995;10:1620-1628.
17. Austin HA III, Boumpas DT, Vaughan EM, Balow JE. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int. 1994;45:544-550.
18. Nossent HC, Henzen-Logmans SC, Vroom TM, Berden JH, Swaak TJ. Contribution of renal biopsy data in predicting outcome in lupus nephritis: analysis of 116 patients. Arthritis Rheum. 1990;33:970-977.
19. Mittal B, Rennke H, Singh AK. The role of kidney biopsy in the management of lupus nephritis. Curr Opin Nephrol Hypertens. 2005;14:1-8.
20. Nzerue CM, Hewan-Lowe K, Pierangeli S, Harris EN. "Black swan in the kidney": renal involvement in the antiphospholipid antibody syndrome. Kidney Int. 2002;62:733-744.
21. Appel GB, Cohen DJ, Pirani CL, Meltzer JI, Estes D. Long-term follow-up of patients with lupus nephritis: a study based on the classification of the World Health Organization. Am J Med. 1987;83:877-885.
22. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive agents in lupus nephritis. J Rheumatol. 1994;21:2046-2051.
23. Austin HA III, Klippel JH, Balow JE, et al. Therapy of lupus nephritis: controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-619.
24. Donadio JV Jr, Holley KE, Ferguson RH, Ilstrup DM. Treatment of diffuse proliferative lupus nephritis with prednisone and combined prednisone and cyclophosphamide. N Engl J Med. 1978;299:1151-1155.
25. Boumpas DT, Austin HA III, Vaughn EM, et al. Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet. 1992;340:741-745.
26. Steinberg AD, Steinberg SC. Long-term preservation of renal function in patients with lupus nephritis receiving treatment that includes cyclophosphamide versus those treated with prednisone only. Arthritis Rheum. 1991;34:945-950.
27. Gourley MF, Austin HA III, Scott D, et al. Methylprednisolone and cyclophosphamide, alone or in combination, in patients with lupus nephritis: a randomized, controlled trial. Ann Intern Med. 1996;125:549-557.
28. Mok CC, Wong RW, Lai KN. Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis. 2003;62:799-804.
29. Illei GG, Austin HA, Crane M, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome without adding toxicity in patients with lupus nephritis. Ann Intern Med. 2001;135:248-257.
30. Petri M. Cyclophosphamide: new approaches for systemic lupus erythematosus. Lupus. 2004;13:366-371.
31. Hellmann DB, Petri M, Whiting-O'Keefe Q. Fatal infections in systemic lupus erythematosus: the role of opportunistic organisms. Medicine (Baltimore). 1987;66:341-348.
32. Mok CC, Lau CS, Wong RW. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum. 1998;41:831-837.
33. Boumpas DT, Austin HA III, Vaughan EM, Yarboro CH, Klippel JH, Balow JE. Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy. Ann Intern Med. 1993;119:366-369.
34. Blumenfeld Z, Shapiro D, Shteinberg M, Avivi I, Nahir M. Preservation of fertility and ovarian function and minimizing gonadotoxicity in young women with systemic lupus erythematosus treated by chemotherapy. Lupus. 2000;9:401-405.
35. Slater CA, Liang MH, McCune JW, Christman GM, Laufer MR. Preserving ovarian function in patients receiving cyclophosphamide. Lupus. 1999;8:3-10.
36. Blumenfeld Z. Ovarian rescue/protection from chemotherapeutic agents [abstract]. J Soc Gynecol Investig. 2001;8(suppl):S60-S64.
37. Dooley MA, Patterson CC, Hogan SL, et al. Preservation of ovarian function using depot leuprolide acetate during cyclophosphamide therapy for severe lupus nephritis [abstract]. Arthritis Rheum. 2000; 43(suppl):2858.
38. McCune J, Somers EC, Ognenovski V, Christman G. Use of leuprolide acetate for ovarian protection during cyclophosphamide therapy of women with severe SLE [abstract]. Arthritis Rheum. 2001;42(suppl) :2006.
39. Fraenkel L, Bogardus S, Concato J. Patient preferences for treatment of lupus nephritis. Arthritis Rheum. 2002;47:421-428.
40. Allison AC, Eugui EM. Mycophenolate mofetil and its mechanisms of action. Immunopharmacology. 2000;47:85-118.
41. Blaheta RA, Leckel K, Wittig B, et al. Mycophenolate mofetil impairs transendothelial migration of allogeneic CD4 and CD8 T-cells. Transplant Proc. 1999;31:1250-1252.
42. Briggs WA, Choi MJ, Scheel PJ Jr. Successful mycophenolate mofetil treatment of glomerular disease. Am J Kidney Dis. 1998;31:213-217.
43. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol. 1999;10:833-839.
44. Halloran P, Mathew T, Tomlanovich S, Groth C, Hooftman L, Barker C; The International Mycophenolate Mofetil Renal Transplant Study Groups. Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, doubleblind, clinical studies in prevention of rejection. Transplantation. 1997;63:39-47.
45. Mycophenolate mofetil (Cellcept) product information. Nutley, NJ: Roche Laboratories; 1995.
46. European Mycophenolate Mofetil Cooperative Study Group. Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet. 1995;345:1321-1325.
47. Sollinger HW; U.S. Renal Transplant Mycophenolate Mofetil Study Group. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation. 1995;60:225-232.
48. Chan TM, Li FK, Tang CS, et al; Hong Kong-Guangzhou Nephrology Study Group. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. N Engl J Med. 2000;343:1156-1162.
49. Appel GB, Ginzler EM, Radhakrishnan J, et al. Multicenter controlled trial of mycophenolate mofetil as induction therapy for severe lupus nephritis [abstract]. J Am Soc Nephrol. 2003;14:38A.
50. Contreras G, Pardo V, Leclercq B, et al. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:971-980.
51. Neylan JF; U.S. Renal Transplant Mycophenolate Mofetil Study Group. Immunosuppressive therapy in high-risk transplant patients: dose-dependent efficacy of mycophenolate mofetil in African-American renal allograft recipients. Transplantation. 1997;64: 1277-1282.
52. Barr RG, Seliger S, Appel GB, et al. Prognosis in proliferative lupus nephritis: the role of socioeconomic status and race/ethnicity. Nephrol Dial Transplant. 2003;18:2039-2046.
53. Dooley MA, Hogan S, Jennette C, Falk R; Glomerular Disease Collaborative Network. Cyclophosphamide therapy for lupus nephritis: poor renal survival in black Americans. Kidney Int. 1997;51:1188-1195.
54. Gelber AC, Christopher-Stine L, Fine DM. Sequential therapies for proliferative lupus nephritis. N Engl J Med. 2004;350:2518-2520.
55. Meng C, Lockshin M. Pregnancy in lupus. Curr Opin Rheumatol. 1999;11:348-351.
56. Moroni G, Quaglini S, Banfi G, et al. Pregnancy in lupus nephritis. Am J Kidney Dis. 2002;40:713-720.
57. Petri M. Prospective study of systemic lupus erythematosus pregnancies. Lupus. 2004;13:688-689.
58. Rahman FZ, Rahman J, Al-Suleiman SA, Rahman MS. Pregnancy outcome in lupus nephropathy. Obstet Gynecol Surv. 2004;59:754-755.